Heron Therapeutics, Inc. (0J4V.L)
USD 2.4
(0.42%)
USD 2.4
(0.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 127.04 Million USD | 17.99% |
| 2022 | 107.67 Million USD | 24.7% |
| 2021 | 86.34 Million USD | -2.59% |
| 2020 | 88.63 Million USD | -39.28% |
| 2019 | 145.96 Million USD | 88.41% |
| 2018 | 77.47 Million USD | 151.81% |
| 2017 | 30.76 Million USD | 2305.55% |
| 2016 | 1.27 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 34.67 Million USD | 1.28% |
| 2024 Q2 | 36.02 Million USD | 3.91% |
| 2023 Q1 | 29.61 Million USD | -1.38% |
| 2023 Q3 | 31.43 Million USD | -1.03% |
| 2023 Q4 | 34.23 Million USD | 8.9% |
| 2023 FY | 127.04 Million USD | 17.99% |
| 2023 Q2 | 31.76 Million USD | 7.25% |
| 2022 FY | 107.67 Million USD | 24.7% |
| 2022 Q3 | 26.55 Million USD | -3.88% |
| 2022 Q2 | 27.63 Million USD | 17.79% |
| 2022 Q1 | 23.45 Million USD | 13.57% |
| 2022 Q4 | 30.02 Million USD | 13.07% |
| 2021 Q4 | 20.65 Million USD | -11.08% |
| 2021 Q2 | 22.44 Million USD | 12.11% |
| 2021 Q3 | 23.23 Million USD | 3.51% |
| 2021 FY | 86.34 Million USD | -2.59% |
| 2021 Q1 | 20.01 Million USD | -2.85% |
| 2020 Q3 | 19.96 Million USD | -11.92% |
| 2020 Q4 | 20.6 Million USD | 3.21% |
| 2020 FY | 88.63 Million USD | -39.28% |
| 2020 Q1 | 25.4 Million USD | -27.6% |
| 2020 Q2 | 22.66 Million USD | -10.76% |
| 2019 Q1 | 31.6 Million USD | 9.56% |
| 2019 Q2 | 36.65 Million USD | 16.0% |
| 2019 Q4 | 35.08 Million USD | -17.69% |
| 2019 FY | 145.96 Million USD | 88.41% |
| 2019 Q3 | 42.62 Million USD | 16.27% |
| 2018 FY | 77.47 Million USD | 151.81% |
| 2018 Q4 | 28.84 Million USD | 45.78% |
| 2018 Q3 | 19.78 Million USD | 14.52% |
| 2018 Q2 | 17.27 Million USD | 49.36% |
| 2018 Q1 | 11.56 Million USD | 15.06% |
| 2017 FY | 30.76 Million USD | 2305.55% |
| 2017 Q2 | 8.51 Million USD | 134.31% |
| 2017 Q3 | 8.57 Million USD | 0.73% |
| 2017 Q4 | 10.05 Million USD | 17.28% |
| 2017 Q1 | 3.63 Million USD | 183.97% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | 1.27 Million USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | 1.27 Million USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -701.894% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -3529.829% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -306.554% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -373.638% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -1381.908% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -505.895% |
| Imunon, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | 45.307% |
| Editas Medicine, Inc. | 78.12 Million USD | -62.62% |
| FibroGen, Inc. | 147.75 Million USD | 14.015% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -10584.945% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 93.268% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 89.782% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 79.088% |
| Verastem, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 8.54 Billion USD | 98.513% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 98.713% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 27.911% |
| Homology Medicines, Inc. | -6.65 Million USD | 2010.149% |
| Nektar Therapeutics | 90.12 Million USD | -40.969% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 97.271% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -9.206% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.914% |
| Illumina, Inc. | 4.5 Billion USD | 97.179% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.704% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.152% |
| Waters Corporation | 2.95 Billion USD | 95.703% |
| Biogen Inc. | 9.83 Billion USD | 98.708% |
| Evolus, Inc. | 202.08 Million USD | 37.133% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | -330.701% |
| Geron Corporation | 237 Thousand USD | -53505.063% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 93.051% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 68.188% |
| Myriad Genetics, Inc. | 678.4 Million USD | 81.273% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -250.225% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 96.646% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 94.749% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.031% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 98.141% |
| OPKO Health, Inc. | 863.49 Million USD | 85.287% |
| Exelixis, Inc. | 1.83 Billion USD | 93.058% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 73.663% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 53.051% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 83.87% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 84.68% |
| Blueprint Medicines Corporation | 249.38 Million USD | 49.056% |
| Insmed Incorporated | 305.2 Million USD | 58.375% |
| TG Therapeutics, Inc. | 233.66 Million USD | 45.629% |
| Incyte Corporation | 3.69 Billion USD | 96.562% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 87.892% |